All clinical trials on the European Union Clinical Trials Register (EUCTR) must report their results in the registry within a year of completion. This site tracks who's doing this and who isn't. Learn more »
These trials completed more than 12 months ago and should have reported results. Some have, some have not.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
| Status | Trial ID | Title | Completion date | Category |
|---|---|---|---|---|
| Reported results | 2004-001756-36 | A multicentre, phase III, open-label, randomised study in patients with advanced follicular lymphoma evaluating the benefit of maintenance therapy with Rituximab (MabThera®) after induction of respons... | 2017-12-31 | due-trials |
| Reported results | 2004-002103-32 | Phase III multicentre open-label randomised study of ICE plus Rituximab (R-ICE) versus DHAP plus Rituximab (R-DHAP) in previously treated patients with CD 20 positive diffuse large B-cell lymphoma, el... | 2014-01-16 | due-trials |
| Reported results | 2004-004349-16 | Targeted Intensification by a new preparative regimen for patients with Low-Grade B-Cell Lymphoma utilizing standard dose Ytrium 90 Ibritumomab Tiuxetan (Zevalin) radioimmunotherapy (RIT) combined wit... | 2009-03-01 | due-trials |
| Reported results | 2005-000734-21 | A Phase 2 Study of VELCADE™ in Subjects with Relapsed or Refractory follicular B-cell Lymphoma | 2011-04-18 | due-trials |
| Reported results | 2005-002344-26 | GEMCITABINE-OXALIPLATINE PLUS RITUXIMAB (R-GEMOX) IN REFRACTORY/RELAPSED PATIENTS WITH CD20 POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA, NON ELIGIBLE FOR HIGH-DOSE CHEMOTHERAPY FOLLOWED BY AUTOTRANSPLANTAT... | 2011-04-29 | due-trials |
| Ongoing | 2005-005375-15 | Efficacy of maintenance therapy with rituximab after induction chemotherapy (R-CHOP vs R-FC) for elderly patients with mantle cell lymphoma not suitable for autologous stem cell transplantation | not-yet-due | |
| Reported results | 2006-000454-44 | Etude prospective multicentrique de phase II évaluant l’adjonction du rituximab et du DepoCyte® en intrathécal au protocole de chimiothérapie C5R chez les patients âgés de 18 à 60 ans porteurs de lymp... | 2017-03-16 | due-trials |
| Ongoing | 2006-007066-11 | A phase II study evaluating the efficacy and safety of the farnesyltransferase inhibitor ZARNESTRA® (R115777, tipifarnib) in patients with relapsed , refractory or progressive mantle cell lymphoma not... | not-yet-due | |
| Reported results | 2007-000270-23 | TARGETED INTENSIFICATION BY A PREPARATIVE REGIMEN FOR PATIENTS WITH HIGH-GRADE B-CELL LYMPHOMA UTILIZING STANDARD-DOSE YTTRIUM-90 IBRITUMOMAB TIUXETAN (ZEVALIN) RADIOIMMUNOTHERAPY (RIT) COMBINED WITH ... | 2014-01-29 | due-trials |
| Ongoing | 2007-000699-18 | Randomized phase II study of two associations of rituximab and chemotherapy, with a pet-driven strategy, in patients from 18 to 59 with DLBCL CD20+ lymphoma and 2 or 3 adverse prognostic factors of th... | not-yet-due | |
| Reported results | 2007-001519-52 | Randomized study of intensified CHOP plus Rituximab (R-CHOP given every 14 days: R-CHOP 14) versus CHOP plus Rituximab given every 21 days (R-CHOP 21) and randomized study of frontline-prophylatic Dar... | 2012-04-06 | due-trials |
| Reported results | 2007-001589-34 | Phase II study of mini CHOP plus Rituximab in non previously treated patient aged over 80 years with CD20+ Diffuse Large B-cell Lymphoma | 2010-06-25 | due-trials |
| Exempt, with results | 2007-007698-22 | A PHASE IB/II STUDY OF ESCALATING DOSES OF REVLIMID IN ASSOCIATION WITH R-CHOP (R2-CHOP) IN THE TREATMENT OF B-CELL LYMPHOMA | 2015-11-23 | not-yet-due |
| Reported results | 2008-008202-52 | DOUBLE BLIND RANDOMIZED PHASE III STUDY OF LENALIDOMIDE (REVLIMID®) MAINTENANCE VERSUS PLACEBO IN RESPONDING ELDERLY PATIENTS WITH DLBCL AND TREATED WITH R-CHOP IN FIRST LINE | 2019-09-30 | due-trials |
| Reported results | 2009-017279-77 | Randomized Phase III study evaluating the non-inferiority of a treatment adapted to the early response evaluated with 18F-FDG PET compared to a standard treatment, for patients aged from 18 to 80 year... | 2020-05-23 | due-trials |
| Reported results | 2009-017995-26 | PHASE II STUDY OF MINI-CHOP PLUS OFATUMUMAB (O) IN NON PREVIOULSY TREATED PATIENTS AGED OVER 80 YEARS WITH CD 20+ DIFFUSE LARGE B-CELL LYMPHOMA | 2014-04-28 | due-trials |
| Reported results | 2010-020757-14 | A multicentric phase II study evaluating the benefit of a short induction treatment by Bendamustine and Rituximab followed by maintenance therapy with rituximab In Elderly (≥ 60 years old) patients wi... | 2016-07-01 | due-trials |
| Reported results | 2011-001356-10 | STUDY OF THE EFFICACY AND SAFETY OF FIRST LINE TREATMENT WITH CHOP AND LENALIDOMIDE (Rev-CHOP) IN PATIENTS AGED FROM 60 TO 80 YEARS WITH PREVIOUSLY UNTREATED ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA (AITL)... | 2019-03-21 | due-trials |
| Ongoing | 2011-002792-42 | A phase 3 open label randomized study to compare the efficacy and safety of rituximab plus lenalidomide ( CC-5013) versus rituximab plus chemotherapy followed by rituximab in subjects with previously ... | not-yet-due | |
| Exempt, with results | 2011-003849-18 | A MULTI-CENTER, PHASE IB/II, OPEN LABEL, SINGLE ARM STUDY OF INOTUZUMAB OZOGAMICIN PLUS RITUXIMAB (R-CMC544) ALTERNATING WITH GEMCITABINE-OXALIPLATIN PLUS RITUXIMAB (R-GEMOX) IN PATIENTS AGED FROM 18 ... | 2016-03-22 | not-yet-due |
| Exempt, with results | 2011-005150-62 | A Phase Ib/II study of OBINUTUZUMAB combined with LENALIDOMIDE for the treatment of relapsed/refractory follicular and Aggressive (DLBCL and MCL) B-cell Lymphoma. Etude de phase Ib/II de l’Obinutuz... | 2022-05-20 | not-yet-due |
| Ongoing, reported early | 2011-005851-15 | A RANDOMIZED PHASE III STUDY USING A PET-DRIVEN STRATEGY AND COMPARING GA101 OR RITUXIMAB IN COMBINATION WITH A CHEMOTHERAPY DELIVERED EVERY 14 DAYS (ACVBP OR CHOP) IN DLBCL CD20+ LYMPHOMA UNTREATED P... | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2012-001580-68 | Phase 3 Multi-Center Randomized Study to Compare Efficacy and Safety of Romidepsin-CHOP (Ro-CHOP) versus CHOP in patients with Previously Untreated Peripheral T-Cell Lymphoma. Ensayo clínico multic... | 2022-12-13 | bad-data |
| Ongoing | 2012-002542-20 | Efficacy of alternating immunochemotherapy consisting of R-CHOP + R-HAD versus R-CHOP alone, followed by maintenance therapy consisting of additional lenalidomide with rituximab versus rituximab alone... | not-yet-due | |
| Reported results | 2012-004246-15 | A Phase II study of oral JAK1/JAK2 inhibitor INC424 in adult patients with relapsed/refractory classical Hodgkin’s lymphoma | 2018-06-12 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2013-000182-37 | BRENTUXIMAB VEDOTIN ASSOCIATED WITH CHEMOTHERAPY IN UNTREATED PATIENTS WITH STAGE I/II UNFAVOURABLE HODGKIN LYMPHOMA - A RANDOMIZED PHASE II LYSA-FIL-EORTC INTERGROUP STUDY | 2022-06-02 | bad-data |
| Reported results | 2013-000450-22 | Sub-cutaneous Rituximab-miniCHOP versus Sub-cutaneous Rituximab-miniCHOP + lenalidomide (R2-miniCHOP) in Diffuse Large B Cell Lymphoma for patients of 80 years old or more. A multicentric phase III st... | 2021-02-22 | due-trials |
| Reported results | 2013-000734-35 | Brentuximab vedotin as consolidation treatment in patients with stage I/II Hodgkin’s lymphoma and FDG-PET positivity after 2 cycles of ABVD Brentuximab vedotin en traitement de consolidation chez d... | 2020-07-09 | due-trials |
| Exempt, with results | 2013-000771-33 | BIBLOS (BTK Inhibition in B-cell LymphOmaS) BIBLOS (inhibition BTK dans les lymphomes à cellules B) | 2018-12-22 | not-yet-due |
| Reported results | 2014-000128-22 | A randomized phase III trial evaluating two strategies of rituximab administration for the treatment of first line/low tumor burden follicular lymphoma (Follicular Lymphoma IV/SC Rituximab Therapy) ... | 2021-06-29 | due-trials |
| Reported results | 2014-001002-17 | A prospective phase II study of bendamustine in patients aged over 60 years with classical Hodgkin lymphoma treated by prednisone, vinblastine, and doxorubicin Etude prospective de phase II évaluan... | 2020-11-10 | due-trials |
| Exempt, with results | 2014-002722-13 | Phase I/II feasibility study of Brentuximab Vedotin in refractory / relapsed Hodgkin lymphoma patients who are treated by chemotherapy (ICE) in second line and eligible for autologous transplantation ... | 2021-07-12 | not-yet-due |
| Ongoing | 2016-000548-33 | Phase II study to evaluate the efficacy of upfront obinutuzumab in mantle cell lymphoma patients treated by DHAP followed by autologous transplantation plus obinutuzumab maintenance then MRD driven ma... | not-yet-due | |
| Exempt | 2016-001499-31 | A Phase Ib-II Study of tazemetostat (EPZ-6438) in newly diagnosed Diffuse Large B Cell Lymphoma (DLBCL) or high risk Follicular Lymphoma (FL) patients treated by R-CHOP Etude de phase Ib-II du taze... | not-yet-due | |
| Exempt, with results | 2016-003103-56 | A phase Ib - II study of Entospletinib (ENTO) in newly diagnosed Diffuse Large B Cell Lymphoma (DLBCL) patients with aaIPI ≥1 treated by R-CHOP | 2019-10-18 | not-yet-due |
| Not reported | 2016-005061-31 | A PHASE II TRIAL EVALUATING COMBINATION OF ATEZOLIZUMAB, WITH VENETOCLAX AND OBINUTUZUMAB FOR RELAPSED/REFRACTORY LYMPHOMAS ETUDE DE PHASE II EVALUANT LA COMBINAISON ATEZOLIZUMAB, AVEC VENETOCLAX ... | 2022-08-24 | due-trials |
| Not reported | 2017-000409-19 | A phase II study of brentuximab vedotin in patients with relapsed or refractory peripheral T-cell lymphoma treated with gemcitabine followed by brentuximab vedotin maintenance Etude de phase II du ... | 2022-10-08 | due-trials |
| Ongoing | 2017-000719-17 | A multicentre, phase II, open label, single arm study of pixantrone in patients with CD20-positive relapsed or refractory aggressive non-Hodgkin lymphoma treated with rituximab, ifosfamide and etoposi... | not-yet-due | |
| Reported results | 2017-001939-38 | A prospective phase II study of nivolumab alone, or in combination with vinblastin in patients aged 61 years and older, with classical Hodgkin Lymphoma and coexisting medical conditions Etude de ph... | 2021-08-12 | due-trials |
| Ongoing | 2017-003909-17 | Randomized Phase 3 Study evaluating the Efficacy and the Safety of Oral Azacitidine (CC-486) compared to Investigator’s Choice Therapy in Patient with Relapsed or Refractory Angioimmunoblastic T cell ... | not-yet-due | |
| Ongoing | 2019-002105-22 | A Phase 2, Multicenter, Open-Label Study of Tislelizumab (BGB-A317) in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma | not-yet-due | |
| Ongoing | 2020-001868-28 | Phase 2, Open-Label Study evaluating Axi-Cel as a 2nd line therapy in patients with Relapsed/Refractory aggressive B-NHL who are ineligible to Autologous Stem Cell Transplantation | not-yet-due | |
| Other | 2020-001985-12 | A Phase II Trial Evaluating Glofitamab, a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas after CAR T-cells therapy | not-yet-due | |
| Ongoing | 2020-003735-16 | A RANDOMIZED NON COMPARATIVE PHASE II STUDY OF LACUTAMAB WITH GEMOX VERSUS GEMOX ALONE IN RELAPSED/REFRACTORY PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA | not-yet-due | |
| Ongoing | 2020-004910-37 | A randomized phase II trial evaluating Ibrutinib plus CD20 Ab and Ibrutinib-Venetoclax plus CD20 Ab in patients with untreated mantle cell lymphoma | not-yet-due | |
| Other | 2020-004977-38 | Phase II, Open-Label Study evaluating efficacy of Tafasitamab and Lenalinomide associated to Rituximab in frontline Diffuse Large B-Cell Lymphoma Patients of 80 y/o or older | not-yet-due | |
| Ongoing | 2020-005225-81 | A PHASE II OPEN-LABEL STUDY EVALUATING VALEMETOSTAT TOSYLATE AS A SINGLE AGENT IN PATIENTS WITH RELAPSE/REFRACTORY B-CELL LYMPHOMA | not-yet-due |